Kan Li1, Richard O'Brien2, Michael Lutz2, Sheng Luo3. 1. Department of Biostatistics, The University of Texas Health Science Center at Houston, Houston, TX, USA. 2. Department of Neurology, Duke University School of Medicine, Durham, NC, USA. 3. Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, USA. Electronic address: sheng.luo@duke.edu.
Abstract
INTRODUCTION: Characterizing progression in Alzheimer's disease is critically important for early detection and targeted treatment. The objective was to develop a prognostic model, based on multivariate longitudinal markers, for predicting progression-free survival in patients with mild cognitive impairment. METHODS: The information contained in multiple longitudinal markers was extracted using multivariate functional principal components analysis and used as predictors in the Cox regression models. Cross-validation was used for selecting the best model based on Alzheimer's Disease Neuroimaging Initiative-1. External validation was conducted on Alzheimer's Disease Neuroimaging Initiative-2. RESULTS: Model comparison yielded a prognostic index computed as the weighted combination of historical information of five neurocognitive longitudinal markers that are routinely collected in observational studies. The comprehensive validity analysis provided solid evidence of the usefulness of the model for predicting Alzheimer's disease progression. DISCUSSION: The prognostic model was improved by incorporating multiple longitudinal markers. It is useful for monitoring disease and identifying patients for clinical trial recruitment.
INTRODUCTION: Characterizing progression in Alzheimer's disease is critically important for early detection and targeted treatment. The objective was to develop a prognostic model, based on multivariate longitudinal markers, for predicting progression-free survival in patients with mild cognitive impairment. METHODS: The information contained in multiple longitudinal markers was extracted using multivariate functional principal components analysis and used as predictors in the Cox regression models. Cross-validation was used for selecting the best model based on Alzheimer's Disease Neuroimaging Initiative-1. External validation was conducted on Alzheimer's Disease Neuroimaging Initiative-2. RESULTS: Model comparison yielded a prognostic index computed as the weighted combination of historical information of five neurocognitive longitudinal markers that are routinely collected in observational studies. The comprehensive validity analysis provided solid evidence of the usefulness of the model for predicting Alzheimer's disease progression. DISCUSSION: The prognostic model was improved by incorporating multiple longitudinal markers. It is useful for monitoring disease and identifying patients for clinical trial recruitment.
Authors: Thomas P A Debray; Yvonne Vergouwe; Hendrik Koffijberg; Daan Nieboer; Ewout W Steyerberg; Karel G M Moons Journal: J Clin Epidemiol Date: 2014-08-30 Impact factor: 6.437
Authors: Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski Journal: Ann Neurol Date: 2009-04 Impact factor: 10.422
Authors: Gary S Collins; Joris A de Groot; Susan Dutton; Omar Omar; Milensu Shanyinde; Abdelouahid Tajar; Merryn Voysey; Rose Wharton; Ly-Mee Yu; Karel G Moons; Douglas G Altman Journal: BMC Med Res Methodol Date: 2014-03-19 Impact factor: 4.615
Authors: Ahsan Bin Tufail; Kalim Ullah; Rehan Ali Khan; Mustafa Shakir; Muhammad Abbas Khan; Inam Ullah; Yong-Kui Ma; Md Sadek Ali Journal: J Healthc Eng Date: 2022-02-11 Impact factor: 2.682